Search academic texts

Information × Registration Number 0225U000339, (0122U000581) , R & D reports Title To study effects of COVID-19 on the course of recurrent and chronic bronchopulmonary diseases in children and work out ways for prevention of unfavorable consequences popup.stage_title Вивчити вплив COVID-19 на перебіг рецидивуючих та хронічних бронхолегеневих захворювань у дітей і розробити шляхи профілактики несприятливих наслідків Head Rechkina Olena O., Доктор медичних наук Registration Date 09-01-2025 Organization State organization "National scientific center of phthisiatry, pulmonology and allergology named after F. G. Yanovskyi National academy of medical sciences of Ukraine" popup.description1 Develop an algorithm for the management of children with recurrent and chronic bronchopulmonary diseases to prevent possible adverse effects caused by COVID-19. popup.description2  The object of the study is 145 children with recurrent and chronic bronchopulmonary diseases who became ill with COVID-19. The purpose of the work is to develop an algorithm for the management the children with recurrent and chronic bronchopulmonary diseases (CBD) to prevent adverse consequences after COVID-19. Research methods are clinical, questionnaire, mathematical, statistical. The most common symptoms of COVID-19 in children with recurrent bronchitis (RB) and bronchial asthma (BA) were established, leading was a dry cough – 92,0%. The frequency of post-COVID syndrome (PS) in children with CBD was determined, which reached 17,1% and didn’t depend on the COVID-19 severity. PS was manifested by dry cough in 12,8% of children, general weakness in 10,0%, headache and decreased cognitive abilities in 4,3%. 15,5% of children with BA had hidden bronchospasm (BS), detected in the bronchodilation test with salbutamol (BDT) by an increase in forced expiratory volume in the first second (FEV1) up to ≥12,0%. A method of detecting PS in children with CBD by used the questionnaire has been developed. PS was established in 13,3% of patients that makes it possible to take timely measures to prevent the adverse consequences of COVID-19. An algorithm for the management of children with CBD who became ill with COVID-19 and continue to cough has been developed, which involves the appointment of personalized therapy schemes in addition to the main treatment or as monotherapy. Patients with RB and BA, who had an increase in FEV1<12,0% in the BDT use Ectoin inhalations, which allows to reduce the intensity of cough by 2,1 times and get rid of cough in 33,3%. BA with an increase in FEV1≥12,0% in the BDT increase the scheme of basic therapy by 1 step up with subsequent correction after 1 month under the control of external respiratory function and clinical symptoms of BA, which reduces the frequency of BS by 3,5 times. Field of application – pediatrics, pulmonology, allergology. Product Description popup.authors Kravtsova Oksana M. Promska Nataliia V. Rechkina Olena O. Rudenko Serhii M. Stryzh Vira O. Tverdokhlib Tetiana O. popup.nrat_date 2025-01-09 Close